Low desire and erectile difficulties are clues, not testosterone diagnoses. Learn how repeat testing, health context and treatment evidence shape assessment.
About 30% of men with an initially low testosterone result have a normal result when retested, according to the Endocrine Society guideline. That matters because one blood result may appear to explain a sexual change before the finding has been confirmed. The assumption that low desire or erectile difficulties establish low testosterone overlooks both the need for confirmation and the broader health picture.
Low desire and erectile difficulties can occur with testosterone deficiency. But the Endocrine Society guideline describes them as suggestive symptoms, not specific signs that establish a diagnosis. Diagnosis requires compatible symptoms or signs alongside clearly and consistently low testosterone.
Both parts of that requirement matter. A sexual concern alone does not identify its cause. A low laboratory result alone does not establish that testosterone explains the concern.
Desire and erections also need separate attention. Desire concerns sexual interest, while erectile function is a different aspect of sexual experience. A person may notice a change in one without a change in the other. Treating them as interchangeable loses information that matters to assessment.
The European Association of Urology recommends checking testosterone as part of an assessment for erectile difficulties. That supports including hormone testing in the right clinical context. It does not make an erectile difficulty a hormone diagnosis before testing has taken place.
A more useful starting point is to describe what has changed rather than select an explanation. For readers trying to put that difference into words, a resource on noticing patterns in sexual function can help frame the conversation.
The Endocrine Society recommends an accurate fasting morning testosterone measurement. A low result should be followed by another fasting morning measurement to confirm it. Repetition is part of establishing a consistent finding, not an optional extra after a diagnosis has already been made.
The reason is practical: testosterone varies from day to day, and food or glucose can suppress the measured level. The guideline therefore asks clinicians to consider how a sample was collected as well as the result itself. A number has more meaning when its testing conditions are understood.
Timing also involves health circumstances. The guideline advises against testing during acute illness or short-term use of testosterone-suppressing medicines such as opioids. These are matters for a clinician to consider when deciding when an assessment will be informative.
Sometimes interpretation involves more than total testosterone. The guideline says free testosterone may need assessment when total testosterone is near the lower limit or when a condition affects sex hormone-binding globulin, known as SHBG.
Obesity and diabetes are among the conditions associated with lower SHBG in the guideline. Aging and liver disease are associated with higher SHBG, as are some anticonvulsant medicines. These examples show why the same laboratory question may need different interpretation in different health circumstances.
The practical distinction is between obtaining a result and interpreting it. Testing provides evidence. Symptoms and the circumstances around the test help a clinician decide what that evidence means. Sexential’s guide to hormone testing and treatment questions provides further educational context for that discussion.
The Endocrine Society’s evidence review characterized average improvements in libido and erectile function as small. It also described small average improvements in sexual activity and sexual satisfaction. These are related outcomes, but they are not the same outcome.
That distinction matters when reading a treatment headline. An improvement in desire is not automatically evidence of the same improvement in erections. Likewise, a change in sexual activity does not describe every aspect of a person’s sexual wellbeing. The review’s separate measures make it important to ask which outcome improved.
The review also concluded that testosterone does not significantly improve sexual function in men whose testosterone is not in the hypogonadal range. In plain language, this means the range associated with testosterone deficiency. The findings do not support treating testosterone as a general-purpose response to sexual concerns.
The evidence therefore supports a narrower conclusion than “testosterone restores sexual function.” Some sexual outcomes improved in selected men with low testosterone. Understanding who was studied and what was measured is essential to understanding that result.
The findings become more useful when their limits and individual context are considered together. An average treatment effect does not predict one person’s response. Nor does the presence of symptoms alongside a low result prove that every part of a sexual concern has the same explanation.
Testosterone concentrations tend to fall with age, but the decline varies between individuals. The Endocrine Society cautions that age-related symptoms and low results can coexist without a clear causal link. Finding both does not settle whether one caused the other.
The guideline advises against routinely prescribing testosterone to all men aged 65 or older simply because their levels are low. It allows individualized consideration when symptoms and consistently low morning results are present. Age belongs in the assessment, but it is not a substitute for assessment.
The guideline also identifies the severity and duration of deficiency as factors that modify symptoms. This adds another reason not to compare one person’s experience directly with someone else’s laboratory result or treatment story.
The Endocrine Society identifies obesity and systemic illness among factors relevant to low testosterone or its assessment. Sleep disorders also belong in that context. Opioids and glucocorticoids are among the medicines the guideline identifies as relevant.
These details should inform a clinical discussion rather than become another self-diagnosis. A medicine appearing on a relevant list does not establish what explains an individual’s symptoms. It gives the clinician information to consider alongside the concern and the test results.
The Endocrine Society says the Testosterone Trials were not large or long enough to settle prostate or cardiovascular safety outcomes. That limits what those trials establish about safety. It is not proof that treatment is either safe or unsafe for a particular person.
Treatment decisions therefore require a qualified clinician’s assessment of possible benefits and risks in the person’s health context. The evidence does not promise restored desire or erections for every individual. A treatment discussion needs a defined concern, not just a wish to change a laboratory number.
One grounded way to respond to a sexual change is to bring a description of the concern rather than a proposed hormone diagnosis. This leaves room for testing when appropriate while keeping the assessment broader than testosterone alone.
The following questions can help organize that conversation. They are discussion prompts, not a diagnostic checklist or instructions to arrange particular tests independently.
This approach does not require dismissing testosterone or assuming it is the answer. It treats hormonal assessment as one part of understanding a sexual concern. Readers preparing for a consultation can also review what a broader sexual health assessment may involve.
The opening statistic gives an initially low result a different meaning. Rather than a final label, it is a finding that needs confirmation and context. The same principle applies to low desire or erectile difficulties: take the concern seriously without asking one symptom or one number to explain everything.
Reducing sexual concerns to testosterone alone leaves important questions unanswered; Sexential’s educational approach places hormonal information alongside physical, psychological and relationship context. For adults aged 35 to 65 who find these influences difficult to separate, its coverage supports clearer understanding and more informed discussion without assigning a diagnosis or recommending individual treatment.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
The Menopause Society’s 2026 program places lifestyle, sleep and sexual health together. Here is what the agenda and partner research actually report.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
